Session » Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

Date: Monday, November 14, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1651

A Case Series on Patients on Tofacitinib in Combination with a Biologic

9:00AM-11:00AM: Abstract Number: 1604

a First-in-Human Study of CR6086, a New Potent EP4 Prostanoid Receptor Antagonist, Demonstrates Good Safety and Tolerability at Therapeutically Relevant Exposures

9:00AM-11:00AM: Abstract Number: 1587

A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1621

A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Hmpl‑523 in Australian Male Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1592

A Randomized, Double-Blind, Parallel-Group, Phase III Study of Shortening the Dosing Interval of Subcutaneous Tocilizumab Monotherapy in RA Patients with an Inadequate Response to Subcutaneous Tocilizumab Every Other Week

9:00AM-11:00AM: Abstract Number: 1612

Abatacept Targets T Follicular Helper Cells in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1625

Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1638

Antibody Mediated Immunity Drives Response to Methotrexate Treatment in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1582

Assessment of Safety, Pharmacokinetics and Pharmacodynamics of a Novel Anti-CD40 Monoclonal Antibody, CFZ533, in Healthy Volunteers and in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1584

Bari-00074565

9:00AM-11:00AM: Abstract Number: 1593

Baricitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1652

Basement Membrane Remodeling Is Significantly Increased with Rheumatoid Arthritis and Suppressed By IL6 Inhibition: Analysis of Two Phase III Clinical Trial

9:00AM-11:00AM: Abstract Number: 1583

Body Mass Index Does Not Affect Response to Subcutaneous or Intravenous Abatacept in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1589

Body Mass Index Does Not Impact Abatacept Retention in Biologic-Naive Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: A 12-Month Interim Analysis of an Observational, Prospective Study

9:00AM-11:00AM: Abstract Number: 1633

Clinical and Radiographic Outcomes after 3 Years of Sarilumab in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1603

Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1596

Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 1630

Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1636

Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1646

Discontinuation of Methotrexate or Glucocorticoids in Patients with Rheumatoid Arthritis Treated with Tofacitinib: Clinical Efficacy Data from Long-Term Extension Studies

9:00AM-11:00AM: Abstract Number: 1628

Distinct Baseline Serum Molecular Profile and Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Asian-Pacific Patients with Active Rheumatoid Arthritis Despite DMARD or Anti-Tnfα Therapy Across Two Global Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1644

Dose Selection of Filgotinib, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 3 Studies: Exposure-DAS28 and ACR Modeling Approach

9:00AM-11:00AM: Abstract Number: 1597

Dose-Response Modeling Is a Useful Tool to Determine Doses for Phase 3: Experience from Olokizumab

9:00AM-11:00AM: Abstract Number: 1623

Early Effects of Tofacitinib on Bone Homeostasis in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1619

EARTH EXPLORER 2, a Phase IIb Exploratory Study Evaluating Efficacy and Safety of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, and the Tumor Necrosis Factor Antagonist Golimumab in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1640

Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials

9:00AM-11:00AM: Abstract Number: 1586

Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1635

Efficacy and Safety of CT-P10, Rituximab Biosimilar Candidate, and Innovator Rituximab in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks

9:00AM-11:00AM: Abstract Number: 1632

Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1591

Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1609

Efficacy of Tofacitinib in Patients Who Are Inadequate Responders to Disease-Modifying Antirheumatic Drugs According to Early Versus Late Duration of Rheumatoid Arthritis: Post-Hoc Analysis of Data from Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1600

Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib By RAPID3: An Analysis of Data from 6 Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 1594

First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1580

Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry

9:00AM-11:00AM: Abstract Number: 1626

In Real Life Rheumatoid Arthritis Patients, Leflunomide Has Limited Impact As a Second Line DMARD after Methotrexate

9:00AM-11:00AM: Abstract Number: 1611

In Vitro Cellular Profiling of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Reveals a Distinct Phenotypic Signature Compared to Tocilizumab, an Anti–IL-6 Receptor Monoclonal Antibody

9:00AM-11:00AM: Abstract Number: 1649

Influence of Modifiable Risk Factors on the Response to MTX Alone in Early RA Patients

9:00AM-11:00AM: Abstract Number: 1639

Interchangeability of Innovator Rituximab and Its Biosimilar: Results from International Controlled Comparative 1-Year Study in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1608

Lack of Early Change in Disease Activity Score Predicts the Likelihood of Achieving Low Disease Activity at Month 6: Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1618

Leflunomide, Sulfasalazine and Hydroxychloroquine for Rheumatoid Arthritis: Efficacious but Poorly Tolerated

9:00AM-11:00AM: Abstract Number: 1648

Long-Term Clinical, Radiographic and Patient-Reported Outcomes Based on RAPID3 Responses with Tofacitinib at 6 Months

9:00AM-11:00AM: Abstract Number: 1595

Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies

9:00AM-11:00AM: Abstract Number: 1601

Maintenance Treatment Using Abatacept with Dose Reduction after Achievement of Low Disease Activity in Patients with Rheumatoid Arthritis (MATADOR) – a Prospective, Multicentered, Single Arm Clinical Trial

9:00AM-11:00AM: Abstract Number: 1616

Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α Monoclonal Antibody: Long-Term Safety and Efficacy for up to 158 Weeks of Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1606

Metrotexate Treatment Inmunomodulate the Abnormal Cytokine Expression Present in NaïVe Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1614

Monotherapy with Abatacept, Rituximab or Tocilizumab Is Not Associated with a Significantly Lower Long Term Retention Than Combination with Synthetic DMARD: Long-Term Registry Data in 4498 Real-Life Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1627

Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards

9:00AM-11:00AM: Abstract Number: 1598

Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1602

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8 Years

9:00AM-11:00AM: Abstract Number: 1642

Pharmacokinetic-Pharmacodynamic Analysis of GS-4059-Mediated Bruton’s Tyrosine Kinase Inhibition

9:00AM-11:00AM: Abstract Number: 1645

Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of ASP5094, an Anti-Alpha-9-Integrin Monoclonal Antibody, Following Single Intravenous Doses in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1634

Pharmacokinetics and Safety of Three Formulations of Rituximab (CT-P10, US-sourced Innovator Rituximab and EU-sourced Innovator Rituximab) in Patients with Rheumatoid Arthritis: Results from Phase 3 Randomized Controlled Trial over 24 Weeks

9:00AM-11:00AM: Abstract Number: 1629

Pharmacokinetics of ABT-494 with the Once-Daily Extended-Release Tablet Formulation Being Utilized in the Ongoing Rheumatoid Arthritis Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1620

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MEDI4920, a Novel, Engineered CD40 Ligand Antagonist, in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 1605

Pooled Safety and Efficacy of Sarilumab in Rheumatoid Arthritis Patients 65 Years of Age and Older

9:00AM-11:00AM: Abstract Number: 1585

Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib

9:00AM-11:00AM: Abstract Number: 1637

Real-World Use of Tofacitinib in Rheumatoid Arthritis: Data from the Swiss Clinical Quality Management RA Registry

9:00AM-11:00AM: Abstract Number: 1613

Safe and Effective Tocilizumab Therapy in Elderly Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1590

Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1622

Safety and Efficacy of Iguratimod in Patients with Active Rheumatoid Arthritis: A Multicenter, Single-Arm, Open-Label, Real World Study

9:00AM-11:00AM: Abstract Number: 1624

Safety of Surgery in Patients Treated with Tocilizumab for Rheumatoid Arthritis : Data from a French Registry

9:00AM-11:00AM: Abstract Number: 1610

Safety, Tolerability, and Dose-Dependent Inhibition of T-Cell-Dependent Antibody Response with MEDI4920, a Novel, Engineered CD40L Antagonist: Results of a Single-Ascending Dose Study in Healthy Volunteers

9:00AM-11:00AM: Abstract Number: 1631

Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients

9:00AM-11:00AM: Abstract Number: 1615

Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial

9:00AM-11:00AM: Abstract Number: 1599

Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program

9:00AM-11:00AM: Abstract Number: 1641

Survival of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1581

The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1607

The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1647

Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years

9:00AM-11:00AM: Abstract Number: 1643

Tofacitinib: Treatment Outcomes in Seropositive Versus Seronegative Patients in a Phase 3 RA Population

9:00AM-11:00AM: Abstract Number: 1588

Treatment with BI 655064 (Antagonistic Anti-CD40 Antibody) Modulates Clinical and Biomarker Parameters Associated with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 1617

Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 1650

Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].